https://seekingalpha.com/news/3971251-sarepta-stock-jumps-fda-panel-nod-gene-therapy
Sarepta Therapeutics (SRPT) climbed ~29% in the pre-market Monday after an FDA panel endorsed its gene therapy SRP-9001 for Duchenne muscular dystrophy. Read more here.
Create an account or login to join the discussion